Genelabs GL701 Lupus NDA Will Be Complete In Second Half Of 2000
Genelabs' NDA filing plans for the potential lupus treatment GL701 (prasterone) will put the product on track for FDA action in early 2001.
Genelabs' NDA filing plans for the potential lupus treatment GL701 (prasterone) will put the product on track for FDA action in early 2001.